Overview

Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the tolerability and the effect of BIA 9-1067 at steady-state on the levodopa pharmacokinetics in Parkinson's Disease (PD) patients treated with levodopa/dopa-decarboxylase inhibitor.
Phase:
Phase 2
Details
Lead Sponsor:
Bial - Portela C S.A.
Treatments:
Benserazide, levodopa drug combination
Carbidopa
Carbidopa, levodopa drug combination
Levodopa
Opicapone